KMID : 1200020230470030356
|
|
Diabetes & Metabolism Journal 2023 Volume.47 No. 3 p.356 ~ p.365
|
|
Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis
|
|
Kim Hye-Jun
Lee Sang-Jun Sa Soon-Ok Bae Jung-Ho Song Gyu-Seon Lee Chae-Won Kim Ju-Hee Shim Sung-Ryul Hong Myung-Hee Han Hyun-Wook
|
|
Abstract
|
|
|
Background : Little is known about the adverse events (AEs) associated with coronavirus disease 2019 (COVID-19) vaccination in patients with type 2 diabetes mellitus (T2DM).
Methods : This study used vaccine AE reporting system data to investigate severe AEs among vaccinated patients with T2DM. A natural language processing algorithm was applied to identify people with and without diabetes. After 1:3 matching, we collected data for 6,829 patients with T2DM and 20,487 healthy controls. Multiple logistic regression analysis was used to calculate the odds ratio for severe AEs.
Results : After COVID-19 vaccination, patients with T2DM were more likely to experience eight severe AEs than controls: cerebral venous sinus thrombosis, encephalitis myelitis encephalomyelitis, Bell¡¯s palsy, lymphadenopathy, ischemic stroke, deep vein thrombosis (DVT), thrombocytopenia (TP), and pulmonary embolism (PE). Moreover, patients with T2DM vaccinated with BNT162b2 and mRNA-1273 were more vulnerable to DVT and TP than those vaccinated with JNJ-78436735. Among patients with T2DM administered mRNA vaccines, mRNA-1273 was safer than BNT162b2 in terms of the risk of DVT and PE.
Conclusion : Careful monitoring of severe AEs in patients with T2DM may be necessary, especially for those related to thrombotic events and neurological dysfunctions after COVID-19 vaccination.
|
|
KEYWORD
|
|
Adverse effects, COVID-19, Diabetes mellitus, type 2, Vaccines
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|